p53 Selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma

Cancer Research

Volumn 59, Issue 17, 1999, Pages 4369-4374

  Vollmer, Charles M ^b   Ribas, Antoni ^b   Butterfield, Lisa H ^b   Dissette, Vivian B ^b   Andrews, Kahlil J ^b   Eilber, Fritz C ^b   Montejo, Lara D ^b   Chen, Angela Y ^b   Hu, Billy ^b   Glaspy, John A ^b   McBride, William H ^b   Economou, James S ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PROTEIN P53;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; GENE DELETION; GENE MUTATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR REGRESSION; TUMOR SUPPRESSOR GENE; VIRUS ATTENUATION; VIRUS REPLICATION;

ADENOVIRIDAE; ADENOVIRUS E1B PROTEINS; ANIMALS; CARCINOMA, HEPATOCELLULAR; GENES, P53; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; VIRUS REPLICATION;

EID: 0033199168     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Venook, A. P. Treatment of hepatocellular carcinoma: too many options? J. Clin. Oncol., 12: 1323-1334, 1994.
2. Levin, B., and Amos, C. Therapy of unresectable hepatocellular carcinoma. N. Engl. J. Med., 332: 1294-1296, 1995.
3. Sugioka, A., Tsuzuki, T., and Kanai, T. Postresection prognosis of patients with hepatocellular carcinoma. Surgery (St. Louis), 113: 612-618, 1993.
4. Tabor, E. Tumor suppressor genes, growth factor genes, and oncogenes in hepatitis B virus-associated hepatocellular carcinoma. J. Med. Virol., 42: 357-365, 1994.
5. Levine, A. J., Momand, J., and Finlay, C. A. The p53 tumour suppressor gene. Nature (Lond.), 351: 453-456, 1991.
6. Okuda, T., Hirohashi, K., Kinoshita, H., Wakasa, K., and Sakurai, M. Characteristic histologic features of human hepatocellular carcinoma with mutant p53 protein. World J. Surg., 20: 215-220, 1996.
7. Sarnow, P., Ho, Y. S., Williams, J., and Levine, A. J. Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell, 28: 387-394, 1982.
8. Yew, P. R., and Berk, A. J. Inhibition of p53 transactivation required for transformation by adenovirus early IB protein. Nature (Lond.), 557: 82-85, 1992.
9. Barker, D. D., and Berk, A. J. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology, 156: 107-121, 1987.
10. Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., and McCormick, F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (Washington DC), 274: 373-376, 1996.
11. Heise, C., Sampson-Johannes, A., Williams, A., McCormick, F., Von Hoff, D. D., and Kirn, D. H. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med., 3: 639-645, 1997.
12. Hall, A. R., Dix, B. R., O'Carroll, S. J., and Braithwaite, A. W. p53-dependent cell death/apoptosis is required for a productive adenovirus infection. Nat. Med., 4: 1068-1072, 1998.
13. Aden, D. P., Fogel, A., Plotkin, S., Damjanov, I., and Knowles, B. B. Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature (Lond.), 282: 615-616, 1979.
14. Bui, L. A., Butterfield, L. H., Kim, J. Y., Ribas, A., Seu, P., Lau, R., Glaspy, J. A., McBride, W. H., and Economou, J. S. In vivo therapy of hepatocellular carcinoma with a tumor-specific adenoviral vector expressing interleukin-2. Hum. Gene Ther., 8: 2173-2182, 1997.
15. Bressac, B., Galvin, K. M., Liang, T. J., Isselbacher, K. J., Wands, J. R., and Ozturk, M. Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. Proc. Natl. Acad. Sci. USA, 87: 1973-1977, 1990.
16. Hsu, I. C., Tokiwa, T., Bennett, W., Metcalf, R. A., Welsh, J. A., Sun, T., and Harris, C. C. p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. Carcinogenesis (Lond.), 14: 987-992, 1993.
17. Goodrum, F. D., and Ornelles, D. A. The early region 1B 55-kilodalton oncoprotein of adenovirus relieves growth restrictions imposed on viral replication by the cell cycle. J. Virol., 71: 548-561, 1997.
18. Scheffner, M., Munger, K., Byrne, J. C., and Howley, P. M. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc. Natl. Acad. Sci. USA, 88: 5523-5527, 1991.
19. Toloza, E. M., Hunt, K., Swisher, S., McBride, W., Lau, R., Pang, S., Rhoades, K., Drake, T., Belldegrun, A., Glaspy, J., and Economou, J. S. In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector. Cancer Gene Ther., 3: 11-17, 1996.
20. Bergelson, J. M., Cunningham, J. A., Droguett, G., Kurt-Jones, E. A., Krithivas, A., Hong, J. S., Horwitz, M. S., Crowell, R. L., and Finberg, R. W. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science (Washington DC), 275: 1320-1323, 1997.
21. Graham, F. L., Smiley, J., Russell, W. C., and Nairn, R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol., 36: 59-74, 1977.